#CCR8
Target engagement is only half the story for anti-CCR8 antibodies. Fc-mediated Treg depletion matters too.

genO-hCCR8/hCCL1/hFcγR: tumor growth inhibition + higher CD8/Treg ratio.

📖 www.genoway.com/science/publ...

#CCR8 #Tregs
November 19, 2026 at 3:12 PM
CCR8⁺ regulatory T cell depletion overcomes immune checkpoint blockade resistance in BRCA2-deficient prostate cancer https://www.biorxiv.org/content/10.64898/2026.11.11.765808v1
November 12, 2026 at 8:49 PM
CCR8⁺ regulatory T cell depletion overcomes immune checkpoint blockade resistance in BRCA2-deficient prostate cancer https://www.biorxiv.org/content/10.64898/2026.11.11.765808v1
November 12, 2026 at 8:49 PM
🔬 SITC 2026 is ON!

genOway is at Booth #1213.
Whether you’re working on CCR8, IL-18, FcγR or PD-1, our team is ready to talk preclinical models.

Stop by and say hi!

#SITC26 #ImmunoOncology #PreclinicalResearch
November 6, 2026 at 5:22 PM
Can T cells be turned against tumor suppressor cells?

Just out in Sci Transl Med: CCR8xCD3 T cell-engaging bispecific antibody selectively depletes CCR8-expressing intratumoral regulatory T cells in preclinical mouse models, enabling tumor growth inhibition.

doi.org/10.1126/scitranslmed.aea7127
T cell-mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell-engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models.
Science Translational Medicine
jclub.com.au
November 6, 2026 at 1:12 PM
Dual CCR8/CD3 activity makes therapeutic index the central question. Controls should separate Treg depletion from broad T-cell activation, quantify cytokine release and tissue cross-reactivity, and test whether efficacy persists in immunocompetent models with human-like CCR8 expression.
November 4, 2026 at 11:58 PM
A new bispecific antibody targets both CCR8 to deplete regulatory T cells and CD3 to revitalize the broader anti-tumor T cell armada. It combated multiple tumor types and potentiated immunotherapy in mice while being safe in large animals. #ScienceTranslationalMedicine https://scim.ag/4BxHDZ9
T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models
CCR8xCD3 bispecific antibody potently boosts antitumor immunity by engaging T cells for the depletion of immunosuppressive intratumoral Treg cells.
scim.ag
November 2, 2026 at 7:00 PM
Drug discovery digest, Nov 1 — 21 new articles:
• AbbVie Beats Again on Skyrizi, Rinvoq and Neuroscience and Signals Bolt-Ons, Not Another Allergan
• KRAS G12D inhibitor INCB161734: from oral tool compound to clinic

#DrugDiscovery #MedChem #Pharma #Biotech
Daily digest — 2026-11-01 | The Pharma Digest
Today's digest has 21 items: Science Translational Medicine work on Treg-depleting CCR8 engagers and synNotch CAR T, KRAS G12D and KEAP1–NRF2 chemistry, and Q3 reads from Sanofi, Regeneron, AbbVie and Alnylam. Computational coverage is a single toxicity-benchmark preprint.
pharmadigest.net
November 1, 2026 at 12:48 PM
🚨 $CHRS
On October 28, 2026, Coherus Oncology, Inc. issued a press release announcing the interim clinical data from the TREGCHECKTM development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy.
SEC Filing: CHRS
Click to view the official SEC document.
www.sec.gov
October 29, 2026 at 12:10 PM
【Amazonセール】【スマイルセール】【正規品】ブラウン 洗浄液 8個入 シェーバー アルコール CCR8【Amazon.co.jp限定】が5053円
価格: 5053円
https://otokusalesokuhobin.com/amazon-live-sale-b07j1mwlmn-20260829/
August 28, 2026 at 3:05 PM
🎯 #AACR25 April 28 - Enhanced Antibodies, TCR Constructs, Cytokines and Chimeric Proteins
““Enhanced anti-tumor efficacy via prolonged retention of a novel anti-CCR8/IL2 mutein fusion antibody”, Dr. @elianepiaggio.bsky.social / Egle Therapeutics
👉 www.abstractsonline.com/pp8/#!/20273...
4/4
Program Planner
www.abstractsonline.com
April 28, 2025 at 9:08 PM
🎯 #AACR25 Session Enhanced Antibodies, TCRs, Cytokines & Chimeric Proteins
“Enhanced anti-tumor efficacy via prolonged plasma membrane retention of anti-CCR8/IL2 mutein” – Dr. @elianepiaggio.bsky.social / Egle Therapeutics
👉 www.abstractsonline.com/pp8/#!/20273...
4/4
Program Planner
www.abstractsonline.com
April 28, 2025 at 4:16 PM
Although the business expects its cash position to fund operations for the next 12 months, there's no wiggle room.

More importantly, it cannot fund future development of pipeline assets.

If the CCR8 competitive landscape develops and tagmokitug delivers, then #$CHRS can raise more money. But...
March 10, 2026 at 1:50 PM
Coherus Oncology #$CHRS provided its full-year 2025 business update and outlook for the year ahead yesterday.

The immuno-oncology drug developer is highly dependent on data readouts for two pipeline assets, CCR8 inhibitor tagmokitug & IL-27 inhibitor casdozokitug.

But a financial risk looms...

🧵👇
March 10, 2026 at 1:50 PM
Single-cell chromatin landscape and DNA methylation patterns reveal shared molecular programs in human tumor and non-tumor tissue CCR8+ Treg cells #SingleCell 🧪🧬🖥️
https://www.biorxiv.org/content/10.1101/2025.05.14.653926v1
May 17, 2025 at 4:00 PM
“Ben Meiselas @meiselasb.bsky.social reports on Donald Trump torching his term has policies backfire in the United States and across the world.” -MTN

m.youtube.com/watch?v=cCR8...
PANICKED Trump TORCHES EVERYTHING as BOMBS GO OFF
YouTube video by MeidasTouch
m.youtube.com
August 29, 2025 at 1:36 PM
[3/4] code: LM-108) combined with a PD-1 inhibitor as a second-line treatment for CCR8-positive locally advanced or metastatic gastric cancer/gastroesophageal junction (G/GEJ) adenocarcinoma has successfully completed the
May 6, 2026 at 11:20 PM
[2/4] Hong Kong Stock Exchange that the group's wholly-owned subsidiary Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. independently developed a national Class 1 innovation The Phase III registration clinical trial of the drug kefirumab "CCR8 monoclonal antibody" (development
May 6, 2026 at 11:20 PM
[1/4] 2026-05-07 07:07:04 - [Sino Biopharmaceuticals: The first patient was enrolled in the phase III registration clinical trial of kefiribizumab "CCR8 monoclonal antibody" second-line treatment of gastric cancer] On the morning of May 7, China Biopharmaceuticals announced on the
May 6, 2026 at 11:20 PM
KISS COOL - LES POILS
YouTube video by Ich&Kar
www.youtube.com
October 3, 2025 at 9:34 AM